Evidence map›Paper›PMID 32704576›Full record

ReviewEndocrinology, diabetes & metabolism2020

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review.

Xiaodan Lv, Yongqiang Dong, Lingling Hu, Feiyu Lu, Changyu Zhou, Shaoyou Qin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology, diabetes & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Type 2 diabetes mellitus.Nature reviews. Disease primers · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Xiaodan LvDepartment of Endocrinology China-Japan Union Hospital of Jilin University Changchun China.
Yongqiang DongDepartment of Thyroid Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou China.
Lingling HuDepartment of Endocrinology Ningbo Medical Center Lihuili Eastern Hospital Zhejiang China.
Feiyu LuDepartment of Paediatrics The First Hospital of Jilin University Changchun China.
Changyu ZhouDepartment of Gastroenterology and Hepatology China-Japan Union Hospital of Jilin University Changchun China.
Shaoyou QinDepartment of Gastroenterology and Hepatology China-Japan Union Hospital of Jilin University Changchun China.ORCID https://orcid.org/0000-0003-4811-9767
Union Hospital · CNFirst Affiliated Hospital of Zhengzhou University · CNJilin University · CNNingbo Medical Center Lihuili Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are no licensed drugs for nonalcoholic fatty liver disease (NAFLD), and there is a lack of consensus on the best outcome measures for controlled trials. This systematic review aimed to evaluate the efficacy of GLP-1 RAs in the management of NAFLD, the degree of heterogeneity in trial design and the robustness of conclusions drawn from these clinical trials. We searched publication databases and clinical trial registries through 2 November 2019 for clinical trials with NAFLD. We evaluated improvements in histological findings, noninvasive markers of hepatic steatosis, inflammation, and fibrosis, insulin resistance and anthropometric measures. Our final analysis included 24 clinical trials, comprising 6313 participants with a mean duration of 37 weeks. Four clinical trials, including RCT (n = 1), single-arm studies (n = 2) and case series studies (n = 1), used biopsy-confirmed liver histological change as their end-points. The remaining studies (n = 20) used surrogate end-points. GLP-1 RAs were effective for the improvement in hepatic inflammation, hepatic steatosis and fibrosis. More importantly, GLP-1 RAs showed promise in improving the histological features of NASH. In addition, 8 ongoing trials were identified. In this systematic review of published and ongoing clinical trials of the efficacy of GLP-1RAs for NAFLD, we found that GLP-1 RAs are effective for hepatic steatosis and inflammation, with the potential to reverse fibrosis. Further prospective studies of sufficient duration using histological end-points are needed to fully assess the efficacy of GLP-1 RAs in the management of NAFLD.

Indexed as

glucagon‐like peptide‐1 receptor agonistsnonalcoholic fatty liver diseasetype 2 diabetes

Identifiers

PMID32704576
PMCPMC7375121
OpenAlexW3034296784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.